KOHLI-VENTURES
25.6.2019 10:02:13 CEST | Business Wire | Press release
Tej Kohli, the London-based tech investor and entrepreneur, says that the hype around AI is still premature and that too much hype is creating a “bubble of enthusiasm” that risks causing disillusionment amongst the public when AI products do not start quickly improving their lives as promised. He says that AI will only be able to change the world when there is an accessible user interface which enables more entrepreneurs to build AI products that can enable all people to access the full benefits of the AI economy. This will require concerted international collaboration as well as major capital investment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190625005075/en/
Kohli is ebullient about the prospects of AI to build a better world and has reiterated his belief that an exponential global AI economy could be worth $150 trillion by 2025; but also believes that it is premature to talk about the all-pervasive impact that AI will have on everyday life quite yet.
Kohli says: “The core problem with AI right now is that it does not yet have an accessible and intuitive user interface that allows any individual or company to ‘plug in’ to the AI economy. For AI to become manifest and omnipresent, it needs to be as easy to create AI products as it is to create smartphone apps. Currently it’s like we have all of the parts to build a car right in front of us, but it’s currently far too expensive to put those pieces together and create a car.”
Early technological progression often happens deceptively slowly. New technologies typically become disruptive only when entrepreneurs can intuitively access and use the technology to create new products and applications. The early Internet was almost useless until the first web browsers were launched by Netscape and Microsoft. Very early smartphones had limited functionality until Android and iOS became the dominant smartphone platforms upon which applications could easily be built. The first 3D printer was invented in 1984 but only started making a disruptive impact when contemporary 3D printers became available with an interface equivalent to a home printer that is intuitive, inexpensive and easy to use. Once that an intuitive and accessible interface is available for a technology, its growth often becomes exponential.
Every AI product currently relies on several elements that must work together. The Internet of Things is needed to connect sensors and other sources of data collection to enable learning. Big modalities of data then have to be stored in The Cloud and made available for access at high speed across 5G speed networks. Algorithms then need to be programmed to create probabilities and patterns and stochastics from collected data, and finally an output is required – most likely as some form of robotics – for AI to use its intelligence to take actions.
Whilst all of these things are currently accessible in ways that they never have been before, with cloud-based processors and the advent of 5G removing almost all cost barriers, and platforms like G2 enabling software developers to start integrating AI into their products and applications, making all of these ‘parts’ work together remains stubbornly expensive.
Kohli says: “The missing component is knowledge. We need more people working on solutions that dematerialise all of the separate components of AI into a user-friendly platform. Only then can it be democratised and used by entrepreneurs to build AI products. Whoever is able to do this first will have an unprecedented competitive advantage over all others.”
In 2018 the United Kingdom Government established the official ‘Office for Artificial Intelligence’ and announced £115m plans to fund 1,000 postgraduate students to study AI. But the UK still faces a massive skills shortage in the tech sector. According to the 2019 Morgan McKinley Salary Guide for Technology, demand means that permanent AI professionals can expect a 20.7% pay increase when switching positions.
In an attempt to create an accessible AI platform, IBM has made its Watson-branded AI services a free open source resource in The Cloud. But in February 2019 IBM had to start allowing enterprises to download Watson onto their own servers, in part to ameliorate the ongoing and expensive challenge of fusing many sources of Big Data into new AI products.
On 9 June United Technologies announced that its aerospace division will merge with defence contractor Raytheon so that the combined companies can “enjoy enhanced resources and financial flexibility to support significant R&D and capital investment”. By collaborating, United and Raytheon say that they will be able to work on a range of new advances in artificial intelligence. But the merger also highlights the sheer magnitude of capital investment that is needed to start making the visible components of AI work together to create AI products.
Data supports this view. A March 2019 survey of 2,830 ‘AI’ tech companies in 13 EU countries found that 40 per cent of those describing themselves as “AI start-ups” had no evidence of any machine-learning technologies that were “material” to what they actually did.
Kohli says: “AI could impact and improve lives many times over compared to the digital revolution. I prefer to call AI ‘alternate intelligence’ because it is not so artificial, it is much more precise and accurate and reliable than human intelligence. But to become omnipresent AI first needs to be demonetised, dematerialised and then democratised. If it becomes omnipresent across healthcare, biotech, hospitality, retail and thousands of other industries, AI could hugely improve everything about human life. But people will first need to be fully woken up to the vast possibilities for ‘alternate intelligence’ to significantly improve their lives. They will need to be willing to make the decision to let AI into their lives. But if their first experiences are overhyped, and then AI products do not start quickly improving their lives as promised, then the risk is that they will start to turn off AI before it even gets started.”
Kohli is an engineer by training who studied at the Indian Institute of Technology. Described as the equivalent of “Harvard, MIT and Princeton combined into one institution”, Kohli’s contemporaries at ITT comprise a ‘who’s who’ of technology pioneers and business leaders, including Vinod Khosla, who founded Sun Microsystems. Kohli himself has a long track record for spotting new trends and getting in early. He first made his fortune during the dotcom boom. When he saw the early potential for cities like Berlin to become new global hubs of technology, he invested heavily into real estate. When his son introduced him to esports, a hyper-growth global phenomenon, Kohli invested €20m into Europe’s leading esports team.
“We are so nearly there” says Kohli, “All of the pieces of AI are visible, and we know how they need to work together, but we haven’t quite solved the economics for allowing any individual or company to easily ‘plug in’ to the AI economy and develop their own AI products. Though there are a lot of people, including myself, who are investing in trying to get us there.”
As an example, Kohli points to Seldon, a London-based tech company that is backed in part by Rewired, an investment fund that counts Kohli amongst its lead investors. Seldon has developed the world’s first open source machine learning platform to enable data scientists, developers and large organisations to share data and harness the network effect to enable machines to learn faster, bigger and better. This will enable companies to create and implement AI products, and Kohli predicts it will propel Seldon into quickly becoming a huge business.
Kohli also points to Aromyx, a US-based company whose early technology was funded by DARPA, but which is now backed by Rewired. Aromyx is developing technologies that will enable the measurement and digitisation of taste and scent, which will allow for the detection and capture of new data modalities for the machine learning that is essential for AI. If successful, the US company will own the world’s platform for the capture and transfer of scent and taste data into AI products, with many enterprise, defence and consumer applications.
As for the more sensational aspect of artificial intelligence: the question of whether AI will one day subjugate the human race, Kohli is unequivocal: “AI is not about tech. AI is about making every industry and everything that is around us perform better, with minimal human input. Humans will always be in control of AI and will always have the ultimate say.”
About Tej Kohli
Tej Kohli is a London-based technology and real estate entrepreneur, businessman and philanthropist who now focuses on visionary ventures and investments that have the potential to transform lives and change the world. Through his investment vehicle Kohli Ventures, Mr Kohli targets high-impact investments into AI, robotics, biotech, genomics and Fintech that help to solve the world’s most pressing challenges and create a better tomorrow.
Mr Kohli also has a well-publicized mission to cure corneal blindness worldwide by 2030 through the philanthropic Tej Kohli Foundation that provides direct support for the Tej Kohli Cornea Institute, a preeminent global institute for solving corneal blindness worldwide.
Mr Kohli is a Distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering. He first rose to success during the dotcom boom selling technology solutions and e-commerce payments software.
About Rewired
Rewired is a robotics-focused venture studio specializing in applied science and technologies. Rewired launched in 2017 with an initial $100m fund for technologies that will enable robots to interact properly with real-world environments. In backing the development of robots’ sensory capabilities and understanding of the world around them Rewired seeks to play a major part in enabling the safe and efficient integration of AI into everyday life.
A video about Rewired can be accessed here: https://youtu.be/6yc5EcBIU5U
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20190625005075/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
